Introduction: Autoimmune atrophic gastritis (AAG) is a condition that compromises the gastric mucosa, leading to atrophy and hypochlorhydria, with a potential increased risk of gastric cancer (GC), especially in the presence of intestinal metaplasia, dysplasia, and Helicobacter pylori (Hp) infection. Studies indicate that chronic inflammation, mediated by CD4+ T lymphocytes and alterations in the gastric microbiome, may promote malignancy. The biomarker ANPEP/CD13, expressed in metaplastic cells, has been associated with the carcinogenic potential of both AAG and Hp-induced gastritis. Objectives: This study evaluates ANPEP/CD13 expression by NGS in samples of gastric cancer (GC), tumor-adjacent tissue (ADJ), and metaplasia (MP), aiming to elucidate the mechanisms of malignant transformation in AAG, with particular attention to the role of Hp. Methods: A total of 124 GC and 62 ADJ samples from patients who underwent surgical resection, and 20 MP samples obtained via endoscopic biopsy at the João de Barros Barreto University Hospital were analyzed. RNA-seq was conducted in a paired-end manner on the NextSeq® platform (Illumina®, US). The NextSeq® 500 MID Output V2 kit – 150 cycles (Illumina®) was used according to the manufacturer’s instructions. Human transcript reads were characterized through alignment and quantification using Salmon v1.5.2, with the coding transcripts from hg v38 (www.ensembl.org) as the reference index and GENCODE v.42 (www.gencodegenes.org) as annotation. The reads were imported from Salmon into RStudio using the Tximport v3.14.0 package. Results: ANPEP expression was significantly higher in MP samples compared to GC and ADJ samples (p<0.0001, Kruskal-Wallis test, adjusted by Benjamini-Hochberg). A trend toward lower survival was observed in patients with high ANPEP expression (p=0.073, Kaplan-Meier), suggesting a possible association between elevated expression of this gene and poorer prognosis. No significant differences were found between ANPEP expression and H. pylori status, tumor staging, location, grade of differentiation, or subtype. These results suggest that ANPEP is an important marker of pre-neoplastic lesions, corroborating the literature that highlights this gene as a biomarker of metaplastic cells in Hp-induced gastritis and AAG. Its higher expression in metaplasia reinforces its relevance for early detection and risk stratification in patients with chronic gastritis. The lack of association with Hp may be influenced by false-negative diagnoses due to the coccoid form of the bacterium under hypochlorhydric conditions, as seen in AAG and GC. Conclusion: The findings of this study support the importance of ANPEP in the early detection of GC risk in patients with chronic gastritis. However, the relationship with AAG and the influence of Hp require further investigation, especially considering the possibility of false-negative results for Hp.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
